Celltrion intends to analyse neutralising titers against other emerging SARS-CoV-2 strains, including the Brazil variant. Credit: Elchinator from Pixabay.

Celltrion has reported that its regdanvimab (CT-P59) demonstrated neutralising potency against emerging SARS-CoV-2 variants first detected in New York, US (B.1.526), Nigeria (B.1.525) and India (B.1.617).

Regdanvimab is a monoclonal antibody being developed as a Covid-19 treatment candidate.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Korea Disease Control and Prevention Agency (KDCA) reviewed the test by merging the antibody with New York, Nigeria and Brazil (P.1) variants. The host cell was then infected with this combination to detect regdanvimab’s neutralising effect against the variants.

According to the data, the treatment candidate showed a strong neutralising effect against the New York and Nigeria variants.

In an in-vitro pseudo virus assay, the candidate induced neutralising titers against the Indian variant.

Celltrion intends to analyse neutralising titers against other emerging strains, including the Brazil variant, to fight the pandemic as the virus is evolving.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CT-P59 could so far neutralise the SARS-CoV-2 variants first detected in the UK (B.1.1.7), California, US (B.1.427/B.1.429), Brazil (P.2), apart from the six earlier known variant genome mutations (variants S·L·V·G·GH·GR).

Last month, Celltrion reported preliminary results from a pre-clinical study, which showed regdanvimab neutralised the South African variant (B.1.351) of SARS-CoV-2 in an in vivo model.

Celltrion Healthcare Medical and Marketing division head Dr HoUng Kim said: “We are encouraged by these results, which reinforce our confidence that CT-P59 should be effective against these newly detected variants.

“Monoclonal antibodies have the potential to alleviate symptoms and prevent progression to severe disease in patients with mild to moderate Covid-19.”

A Phase III clinical trial to assess efficacy and safety of the treatment candidate has enrolled more than 1,300 subjects in 13 countries including the US, Spain and Romania.

In a separate development, the Center for International Blood and Marrow Transplant Research (CIBMTR) has commenced a large observational study to assess the safety, efficacy and response durability to Covid-19 vaccines in patients with haematological malignancies and non-malignant blood diseases.

Carried out in partnership with the Blood and Marrow Transplant Clinical Trials Network, the study will enrol 732 subjects who were given hematopoietic cell transplantation (HCT) or chimeric antigen receptor (CAR) T-cell therapy in the past 12 months.

Participants should also have received a Covid-19 vaccine.